Supplements maker Prenetics Global's Q3 revenue jumps on IM8 brand growth

By Reuters News


Overview

  • Consumer health company's Q3 2026 revenue rose 228% yr/yr, above company guidance

  • IM8 revenue grew 266% yr/yr, marking seventh consecutive record quarter

  • Adjusted EBITDA loss improved to $12.7 mln, or 20% of revenue, from 39% in Q2


Outlook

  • Prenetics reaffirms FY2026 total revenue guidance of $220–230 mln and IM8 revenue of $215–222 mln

  • Company raises second-half 2026 Adjusted EBITDA loss outlook to $30–35 mln from $8–12 mln

  • Prenetics expects FY2027 IM8 revenue of $400 mln or more, reaffirmed


Result Drivers

  • IM8 GROWTH - IM8 revenue rose 266% yr/yr, with September marking the strongest month ever and a $284 mln annualized revenue run-rate

  • CUSTOMER COHORT RETURNS - Customers acquired in Q1 2025 returned about 4.1x their acquisition cost in gross profit in under two years, above the 3-to-1 benchmark, with newer cohorts on pace to reach it

  • DECLINING CUSTOMER ACQUISITION COST - Customer Acquisition Cost declined for the second consecutive quarter, to approximately $285, on record acquisition spend


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$64.1 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Prenetics Global Ltd is $37.00, about 126.6% above its November 17 closing price of $16.33


Reuters Recommended Reads

  • Nov 18 - China's Tencent Q3 revenue, profit rise on engagement, cloud growth

  • Nov 17 - Fintech Klarna's Q3 revenue beats as active consumers and merchants grow

  • Nov 16 - Chinese EV maker XPeng's Q3 revenue rises 19% on higher deliveries


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.